AI Proteins uses AI-based design and a high-throughput drug discovery platform to create de novo miniproteins for specific therapeutic applications. The company has built a proprietary platform that leverages synthetic biology, robotics, and automation to rapidly design, build, and develop highly specific, durable, and inexpensive miniprotein medicines with the potential for a variety of administration options. Miniproteins combine the most desirable characteristics of small molecules and biologics. Some notable features of miniproteins include their negative charge to reduce off-target tissue binding, low molecular weight to improve tissue penetration and reduce immunogenicity, and highly stable and predictable structures.

<p>AI Proteins uses AI-based design and a high-throughput drug discovery platform to create de novo miniproteins for specific therapeutic applications. The company has built a proprietary platform that leverages synthetic biology, robotics, and automation to rapidly design, build, and develop highly specific, durable, and inexpensive miniprotein medicines with the potential for a variety of administration options. Miniproteins combine the most desirable characteristics of small molecules and biologics. Some notable features of miniproteins include their negative charge to reduce off-target tissue binding, low molecular weight to improve tissue penetration and reduce immunogenicity, and highly stable and predictable structures.</p>


AI Proteins

Founded: 2021
Location: Boston, MA
Employee range: 1-50
Funding: 10-100M

Short description:

Drug notes:

Long description:

Jobs: